Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

TPO-ras for persistent thrombocytopenia following CAR-T therapy in multiple myeloma: A multicenter clinical experience

View Full Paper
Ask AI
Bookmark
Share

Authors

ZCZhaozhao ChenUniversity of MichiganHMHeng MeiUnion Hospital

Discussion

Loading...

Member takes

Overview

Retrospective analysis finds TPO receptor agonists raise platelet counts in multiple myeloma patients after CAR-T therapy, suggesting better management strategies.

Key Points

  • To evaluate the effectiveness of thrombopoietin receptor agonists in treating persistent thrombocytopenia after CAR-T therapy in multiple myeloma patients.
  • Multicenter retrospective study of MM patients receiving CAR-T therapy from 2022-2024.
  • Patients with persistent thrombocytopenia were treated with TPO-RAs including hetrombopag and eltrombopag.
  • Univariate and multivariate analyses were conducted comparing patients with and without thrombocytopenia.
  • 31 of 72 patients developed persistent thrombocytopenia after CAR-T therapy.
  • 22 patients treated with TPO-RAs showed a significant increase in platelet counts (P<0.0001).
  • 36.4% of treated patients achieved resolution of severe thrombocytopenia.

Cite This Study

Chen et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236daa1https://doi.org/10.1182/blood-2025-4077
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Use of Eltrombopag to Improve Thrombocytopenia and Transfusion Requirement in Anti-CD19 Car-T Cell-Treated Patients2024
  2. 2Use of Eltrombopag to Improve Thrombocytopenia and Tranfusion Requirement in Anti-CD19 CAR-T Cell-Treated Patients2024 · 3 citations
  3. 3Efficacy and safety of recombinant human thrombopoietin (rhTPO) for thrombocytopenia induced by combinatorial interventional, targeted, and immunotherapy in hepatocellular carcinoma (SYNERGY-TPOACT): A retrospective cohort study.2026
  4. 4Evaluating the impact of treatment timing with recombinant human thrombopoietin for cancer treatment–induced thrombocytopenia: A retrospective cohort study.2026
  5. 5Off-Label Use of Thrombopoietin Receptor Agonists: Case Series and Review of the Literature2021 · 8 citations